University of Miami's 2nd Biennial Miami Leukemia Symposium

 

MDS Biology and Treatment
25:42

University of Miami's 2nd Biennial Miami Leukemia Symposium

2020 Update on MDS Mutational Landscape: What Are the Most Common MDS-Associated Somatic Mutations? Which Ones Are Potentially Diagnostic? What Is Their Prognostic Value Based on IWG Experience?

FEATURING Rafael Bejar
  • 15 views
  • October 27, 2020
20:06

University of Miami's 2nd Biennial Miami Leukemia Symposium

2020 Update on Splicing in MDS: How Can We Target Spliceosome-Mutant MDS?

FEATURING Timothy Graubert
  • 11 views
  • October 23, 2020
22:02

University of Miami's 2nd Biennial Miami Leukemia Symposium

TGF Beta Pathway Inhibition in MDS: Luspatercept Significantly Decreases Transfusion Dependence in RARS MDS and Stimulates Late Stage of Erythroid Differentiation

FEATURING Amit K. Verma
  • 114 views
  • May 14, 2020
  • 1
12:19

University of Miami's 2nd Biennial Miami Leukemia Symposium

How to Calculate Risk in MDS Patients?

FEATURING Mikkael Sekeres
  • 92 views
  • May 14, 2020
  • 1
14:36

University of Miami's 2nd Biennial Miami Leukemia Symposium

Frontline Therapies in MDS: Leveling Lower-risk MDS

FEATURING Mikkael Sekeres
  • 37 views
  • May 14, 2020
05:28

University of Miami's 2nd Biennial Miami Leukemia Symposium

Frontline Therapies in MDS: Hampering Higher-risk MDS

FEATURING Mikkael Sekeres
  • 19 views
  • May 14, 2020
10:48

University of Miami's 2nd Biennial Miami Leukemia Symposium

Hypomethylating Agents as SoC in MDS/AML: Clearance of TP53 Mutation Can Improve Outcomes

FEATURING David Sallman
  • 19 views
  • May 14, 2020
08:13

University of Miami's 2nd Biennial Miami Leukemia Symposium

Discussion on the Data of Frontline Combination Therapy with APR-246 + Azacitidine in TP53 MT HMA-naive MDS and Oligoblastic AML

FEATURING David Sallman
  • 19 views
  • May 14, 2020
05:21

University of Miami's 2nd Biennial Miami Leukemia Symposium

Magrolimab (Formerly 5F9) is a First-in-class Macrophage Immune Checkpoint Inhibitor Targeting CD47 in R/R AML

FEATURING David Sallman
  • 168 views
  • May 14, 2020
27:33

University of Miami's 2nd Biennial Miami Leukemia Symposium

Overcoming Adaptive Therapy Resistance in AML: IRAK Signalling (via TLR9) Plays a Major Role in the Adaptive Resistance to FLT3 Inhibitors

FEATURING Daniel Starczynowski
  • 19 views
  • May 14, 2020